Many genomic alterations associated with human diseases localize in noncoding regulatory elements located far from the promoters they regulate, making it challenging to link noncoding mutations or risk-associated variants with target genes. The range of action of a given set of enhancers is thought to be defined by insulator elements bound by the 11 zinc-finger nuclear factor CCCTC-binding protein (CTCF). Here we analyzed the genomic distribution of CTCF in various human, mouse and chicken cell types, demonstrating the existence of evolutionarily conserved CTCF-bound sites beyond mammals. These sites preferentially flank transcription factor-encoding genes, often associated with human diseases, and function as enhancer blockers in vivo, suggesting that they act as evolutionarily invariant gene boundaries. We then applied this concept to predict and functionally demonstrate that the polymorphic variants associated with multiple sclerosis located within the EVI5 gene impinge on the adjacent gene GFI1.
a r t i c l e s
Although only a small proportion of the genome codes for proteins and regulatory RNAs, cis-regulatory elements (CREs), the DNA sequences controlling the expression of the coding segments, are located in the vast noncoding portion of the genome 1 . Genome-wide association studies (GWASs) are increasingly linking human diseases to noncoding DNA that probably has regulatory function (reviewed in refs. 2, 3) . However, in these cases, the assignment of the candidate disease gene may not be straightforward: a CRE can act over long distances, and its target gene may not be the one closest to the CRE (see, for example, ref. 4) . Therefore, methods to predict which gene (or genes) is regulated by particular noncoding genome segments should help identify the candidate disease gene when the lesion lies in noncoding regions.
CTCF contributes to the regulation of gene expression and higherorder organization of the genome 5 . It is evolutionarily conserved and widely distributed along the vertebrate and Drosophila melanogaster genomes [6] [7] [8] [9] . Although the primary function(s) of CTCF cannot now be directly derived from its genomic distribution, some of the CTCF-bound sites function as regulatory boundaries, confining the range of actions of CREs to genes within those boundaries (reviewed in refs. 5, 10) . Different cofactors can interact with CTCF, including the SNF2-like chromodomain helicase CHD8 and the DEAD-box RNA helicase p68 (refs. 11,12) . CTCF also binds to the cohesin complex at many genomic sites [13] [14] [15] . Indeed, at several loci, the cohesin complex seems to regulate this insulator activity [13] [14] [15] . Constitutive CTCF-bound sites probably serve this function, whereas more labile sites may be involved in regulating tissue-specific gene expression. In fact, a proportion of CTCF sites are constitutively occupied in several human cell types and are conserved between human and mouse at the sequence level 7, 16 . This conservation might extend even further evolutionarily, because the development of the shared body plan of vertebrates is controlled by a shared set of transcription factors and signaling molecules deployed in similar patterns 17 . However, genomewide CTCF distribution has not yet been examined beyond mammals. If CTCF-bound sites are found at syntenic positions in different vertebrates, these evolutionarily conserved boundaries could be used to a r t i c l e s resolve ambiguous associations of target genes affected by mutation in noncoding regions in human diseases, as is the case of multiple sclerosis and the GFI1 and EVI5 genes (encoding growth factorindependent 1 and ecotropic viral integration site 5, respectively).
Multiple sclerosis (MIM 126200) is the most common progressive and disabling neurological condition affecting young adults in the world today. The overall prevalence of multiple sclerosis is 2-150 per 100,000 individuals. Pathogenetically, multiple sclerosis is an autoimmune disease leading to the demyelination of central nervous system (CNS) axons 18 . Genetically, it is a complex disorder resulting from a combination of genetic and nongenetic factors 19 . In addition to the human leukocyte antigen (HLA), which is the strongest locus for multiple sclerosis in most populations, other genetic factors involved in multiple sclerosis remained elusive until the arrival of GWASs (MSGene Database, http://www.msgene.org/). So far, seven GWASs have been carried out for multiple sclerosis; although study design and results vary substantially among experiments, some new susceptibility genes have been identified and replicated using this approach 20 . However, even after convincing replications, the localization of the causal variant(s) of most of these loci remains to be determined. Several GWASs have found a set of multiple sclerosis-associated polymorphisms belonging to the same linkage disequilibrium block, which is in a region containing GFI1, EVI5, RPL5 and FAM69A (encoding ribosomal protein L5 and family with sequence similarity 69, respectively) [21] [22] [23] . Fine mapping of this genomic region has pointed to polymorphisms within the 17th intron of the EVI5 gene as the most probable causal variants of the association 24 . However, these findings do not clarify the functional role of this EVI5 risk region. Our analysis of the CTCF sites within this genetic block indicates that the 17th intron of the EVI5 gene probably belongs to the GFI1, and not the EVI5, regulatory domain. We further demonstrate that this intron contains CREs that contact GFI1 but not EVI5. We finally show that increased expression of GFI1, but not of EVI5, is associated with the multiple sclerosis risk haplotype. We therefore conclude that GFI1, and not EVI5, is the causal gene associated with multiple sclerosis.
RESULTS

CTCF occupies syntenic positions in vertebrate genomes
An important fraction of CTCF sites in human cells are constitutive: that is, they are occupied by CTCF regardless of the cell type analyzed 7 . We wondered to what extent these constitutive sites are also bound in vivo by CTCF in equivalent syntenic positions (that is, surrounded by the same orthologous genes) across vertebrate genomes. To investigate this, we collected available genome-wide CTCF chromatin immunoprecipitation sequencing (ChIP-Seq) data from human cells (CD4 + , HeLa and Jurkat cells 6, 7 ) and produced CTCF ChIP-Seq data for mouse (Mus musculus) embryonic stem (ES) cells and embryonic fibroblasts (MEFs), as well as for chicken (Gallus gallus) red blood cells isolated from embryos at 5 and 10 d of development. We derived potential CTCF-bound sites from ChIP-Seq using described protocols 6, 7, 25 (see Supplementary Fig. 1 for details) . Within each species, we identified the set of sites common to all cell lines (species-specific constitutive CTCF sites), considering two sites as common between two cell types if their sequences overlapped by ≥50% of their length (see Online Methods for details). A large fraction of CTCF sites seem to be constitutive for the different cell types within each species (Fig. 1a) .
We next wanted to identify the set of constitutive CTCF sites that are, in addition, evolutionarily conserved in all investigated species. 74% and 5% of human constitutive CTCF sites lie within sequences conserved in mouse and chicken, respectively, showing at least 50% identity in pairwise alignments. The global nucleotide coverage is 61.5% and 3.9% in mouse and chicken, respectively, as inferred from multiple sequence alignments of 44 mammalian genomes 26 . However, we reasoned that CTCF-bound sites located at equivalent positions in two species (for example, between two paralogous genes) could have equivalent functions (that is, be evolutionarily conserved), even if the sites did not reside in conserved sequences. Therefore, relying exclusively on sequence conservation was not sufficient to identify these evolutionarily equivalent sites occupied by CTCF. We therefore considered two CTCF sites as equivalent evolutionarily if they were syntenic in two species-that is, if they separated the same evolutionarily conserved regions (ECRs 27 ), either coding or noncoding, at orthologous genome loci (see Online Methods and Supplementary  Fig. 2 ). We found 247 constitutive and syntenic (CONSYN)-CTCF sites among the three investigated genomes (Fig. 1b) . This is probably an underestimate of the number of CONSYN sites because of the stringency in the definition of vicinity to conserved ECRs we used, as well as the relatively low overall degree of sequence conservation between chicken and mammals. Still, these 247 CONSYN-CTCF sites correspond to 7% of the total constitutive sites in chicken, the species with the lowest number of identified CTCF-bound regions. 
a r t i c l e s
Genomic features of CONSYN sites
Next, we analyzed sequence features associated with this set of CTCFbinding sites. We first found that the most overrepresented motifs were three highly similar position weight matrixes that matched the previously established CTCF consensus motif (Fig. 1c) , consistent with the high conservation of the CTCF protein from mammals to birds 28 . Using motif discovery on CONSYN sites (see Online Methods), we identified several additional motifs that are overrepresented in the CONSYN-CTCF set as compared with the species-specific constitutive sites ( Table 1) . This suggests that other nuclear factors may cooperate with CTCF at these sites. Among the top-ranking factors, we found SAP-1a, E2F-1, HIC1 and AP-2. ChIP-Seq data for E2F-1 in mouse 29 confirms that E2F-1 is more frequently found in the vicinity of CONSYN-CTCF sites than near nonconstitutive sites or species-specific constitutive sites (Fig. 1d) . Using a very stringent set of simulated CONSYN sites as a random control (see Supplementary Methods), we found that the association of CONSYN-CTCF sites with E2F-1 sites was statistically significant (P < 0.001).
CTCF sites have been proposed to serve four types of functions: (i) enhancer blockage, (ii) barriers that prevent repressive heterochromatin spreading , (iii) threedimensional genome organization and (iv) transcriptional enhancement 5, 10, [30] [31] [32] . In certain contexts cohesins act as mediators for the enhancer-blocking and/or threedimensional genome organizing activities of CTCF 15 . Conversely, CTCF flanks laminaassociated domains (LADs), where it has been proposed to have a barrier function, preventing the spread of heterochromatin into transcriptionally active chromosomal domains 33 . To determine whether CONSYN-CTCF sites could be linked preferentially to either of these functions, we examined the correlation of these sites with SccI-cohesin and LAD peaks 33 . We found that CONSYN sites overlapped with cohesin-associated loci, but tended not to overlap with LADs, even when we extended the search to up to 10 kb around each LAD site (Fig. 1e) . Both the overlap with cohesin-associated loci and the avoidance of LADs are statistically significant when compared with the control set of simulated CONSYN sites (P < 0.001 in both cases). These data are consistent with CONSYN-CTCF sites having an enhancer-blocking activity. To test this hypothesis, we assayed the insulator activity on six human CTCF sites, three conserved between human and mouse and three CONSYN sites, in two ways, through luciferase enhancer-blocking assays in human HEK293 cells 34, 35 and in vivo, using a recently described insulator assay in zebrafish 36 (Fig. 2) . and CTCF5) and three CONSYN sites (CTCF2, CTCF7 and CTCF8) were assessed for enhancerblocking activity through an in vitro assay 34 . Enhancer-blocking activity (fold enrichment) normalized to the reference pELuc vector ± s.d. The 5′ HS4 chicken β-globin insulator (5′ HS4) and the internal II/III element were used as positive controls. A mutated II/III element with an altered CTCF site was used as a negative control 35 . (b) Enhancer-blocking activity in vivo using a transgenic zebrafish assay in which the insulator is placed between a CNS enhancer and a promoter driving GFP expression in somites. Bars, ratios between fluorescence in somites versus CNS. Only the four CTCF sites with significant insulator activity are shown. (c) Images from zebrafish embryos after microinjection of each of the CTCF sites in b, along with positive (5′ HS4) and negative (empty) controls. Top, construct used.
a r t i c l e s
All six sites showed consistent enhancer-blocking activity in the in vitro assays (more than two-fold; Fig. 2a) and four of them, including the three CONSYN sites, reproducibly showed robust enhancer-blocking activity in vivo (Fig. 2b,c) .
CONSYN sites flank developmental and disease genes
All these facts led us to hypothesize that CONSYN-CTCF sites separate genes whose expression should be tightly regulated and whose chromatin should be organized at the genomic level, at least from chicken to humans. To identify these genes, we assigned two neighboring genes in each direction for each CONSYN site (lists are in Supplementary Table 1) . Using gene ontology term analysis, we identified enrichment in transcription factors involved in cell differentiation and embryonic development (Fig. 3a and Supplementary  Tables 2 and 3) . Indeed, although transcription factors constitute ~5% of all genes in mouse and human genomes, ~12% and 10% of murine and human genes adjacent to CONSYN-CTCF sites are transcription factors. The difference is statistically significant compared with a set of random genomic sites (P < 0.01, Fig. 3b) . We analyzed recent expression data for human and mouse 37 and found that transcription factors flanking CONSYN sites are not preferentially associated with tissue-specific expression patterns (Fig. 3b) . However, we observed that adjacent genes separated by CTCF-binding sites have different patterns of expression as compared with all genes in the genome ( Fig. 4a and Supplementary Fig. 3 ), suggesting that CTCF-bound sites function as regulatory domain boundaries.
Altered regulation of genes is often associated with human diseases 3, 38 . We therefore examined whether the set of genes flanking constitutive CTCF sites is enriched in disease-associated genes. When subjected to MeSH analysis (http://www.nlm.nih.gov/mesh/), the human genes linked to human-mouse conserved CTCF sites and to human-mouse-chicken (CONSYN) sites were significantly associated with disease, including cardiovascular disease, neuroectodermal tumors and lymphomas (Fig. 4b) .
CONSYN sites predict GFI1 association to multiple sclerosis A considerable number of GWASs indicate that many human diseases are caused by mutations in CREs. However, identifying the target gene of each of these CREs is not trivial, because regulatory elements may be located hundreds of kilobases away from its target promoter, and even inside neighboring genes. Thus, the gene implicated in the development of a particular disease often cannot be directly identified. Because CONSYN-CTCF sites seem to define evolutionarily conserved gene-regulatory boundaries and these boundaries are preferentially linked to genes encoding transcription factors whose malfunction is frequently associated with human diseases, we reasoned that these sites could aid in linking mutations or polymorphisms in CREs associated with human diseases to their target 'disease' genes. As a proof of principle, we used the GFI1-EVI5 genomic region, which is associated with multiple sclerosis 21 . The most probable causal variants of the association with a r t i c l e s multiple sclerosis are located in the last intron of the EVI5 gene 24 . Thus, one or several CREs within this intron may be affected in the risk haplotypes. On the basis of this evidence, EVI5 has been suggested to be the potential target of these CREs 22, 23 . However, we examined the human constitutive CTCF-binding sites in the GFI1-EVI5 genomic locus and found three sites separating the risk genomic area from the EVI5 promoter (Fig. 5a) . Strong CTCF-binding sites also separate this last EVI5 intron from its promoter in mouse and chicken genomes, and in similar positions ( Supplementary Fig. 4 ). Although we could not identify these CTCF sites as syntenic sites in our pipeline owing to the stringent criteria imposed, they probably constitute functionally equivalent CTCF sites. The evolutionarily conserved architecture of the GFI1-EVI5 genomic locus, with CTCF-bound sites separating the last intron of EVI5 from its promoter in all vertebrates strongly suggests that potential CREs within this intron preferentially act on the neighboring GFI1 gene, and not on EVI5. Multiple sclerosis is a heterogeneous immunopathy probably caused by the joint participation of different peripheral blood cells in the CNS 39 . Notably, malfunction of GFI1, which encodes a zinc-finger transcription factor, causes abnormal or malignant hematopoiesis (reviewed in ref. 40) , and therefore could have a role in an autoimmune diseases such as multiple sclerosis. To evaluate whether CREs in the last intron of EVI5 act on either the EVI5 or GFI1 promoter, we carried out chromatin conformation capture (3C) assays on control and phorbol myristate acetate plus ionomycin (PMA + Io)-activated human peripheral blood mononuclear cells (PBMCs). In these 3C assays we used several different anchor primers, one on the promoter region of each gene, and multiple primers spanning the whole genomic region of the last EVI5 intron (Fig. 5b) . These primers allow the detection of DNA interactions between different regions across the whole intron and either of the two promoters. We normalized PCR product values for each primer pair against those obtained in control samples containing bacterial artificial chromosome clones spanning the tested genomic region (see Supplementary Methods) . In nonactivated PBMCs, we found no significant interaction between any of the promoters and different regions of the intron (Fig. 5b, blue trace) . The same was true in activated cells when we surveyed the EVI5 promoter (Fig. 5b , cyan trace). In contrast, the GFI1 promoter interacted with several regions of the intron, more strongly in the activated than in the control PBMCs (Fig. 5b , red and orange traces, respectively). These results suggest that the EVI5 intron contains CREs that act on the promoter of GFI1, and not on that of EVI5. Accordingly, GFI1 is robustly upregulated in activated PBMCs, whereas EVI5 is undetectable in both activated and nonactivated blood cells ( Supplementary  Fig. 5 ). In support of this hypothesis, a probable GFI1 hematopoietic stem cell-specific enhancer has recently been identified in this genomic area 41 .
Notably, we predicted from these data that the expression of GFI1, and not that of EVI5, would be altered in individuals carrying a risk haplotype. Indeed, we confirmed this: in PBMCs of the risk (G) allele within single nucleotide polymorphism (SNP) rs11804321, GFI1 expression was greater than in samples carrying the protective (A) allele either heterozygously or homozygously (Fig. 5c) . In contrast, we found no differences in EVI5 expression levels (data not shown). This is consistent with a recent finding that GFI1 expression is also increased in peripheral blood cells of individuals who later develop multiple sclerosis 42 , indicating that increased GFI1 is linked to higher risk of developing the disease. The regions from the EVI5 intron that interact with the GFI1 promoter in our 3C studies contain two evolutionarily conserved noncoding sequence blocks (CNR-A and CNR-B; Fig. 5b) , suggesting a possible regulatory function for these regions. To examine this possibility, we PCR-amplified these two regions and tested their potential enhancer or repressor activities in luciferase assays in THP-1 human acute monocytic leukemia cells. Both regions showed clear repression activity in these assays (Fig. 6a) . Therefore, our results are compatible with a scenario in which an increased risk for multiple sclerosis is caused by a mutation in any of these two, or even other, repressors located in the last EVI5 intron, which would then lead to abnormally high expression of GFI1. a r t i c l e s
Our earlier prediction of a functional linkage between the risk haplotype and GFI1 was based on the location of a potential enhancer barrier separating the risk region and the EVI5 promoter. To test whether any of these three human CTCF-bound sites can function as insulators, we carried out functional enhancer-barrier cell culture assays with all three of them. Much like other CTCF-bound sites we tested, all three regions acted as insulators in these experiments (Fig. 6b) . These results suggest that these CTCF sites are insulators separating GFI1 and EVI5 regulatory landscapes. If so, we expect that reducing CTCF function would affect this boundary, leading to misregulation of either of these two genes. Because organization of GFI1 and EVI5 is syntenic in zebrafish, we tested this possibility by knocking down CTCF function with a splicing-specific morpholino (MOsp1CTCF, see Online Methods and Supplementary Fig. 6 for details) in this organism. The MOsp1CTCF morpholino partially inhibits the correct removal of intron 2. The inclusion of intron 2 in the mRNA introduces several premature stop codons that eliminate key domains of the CTCF protein (Supplementary Fig. 6 ). We then determined by quantitative real-time PCR (qrtPCR) the expression levels of both gfi1 and evi5 genes in control and morphant embryos. In the CTCF morphant embryos the expression of evi5 is higher than in control individuals, whereas that of gfi1 does not vary (Fig. 6c) . These results indicate that reducing CTCF causes evi5 misregulation, which could be due to inappropriate contact with neighboring regulatory regions. Because the genomic organization of these two genes is conserved throughout vertebrate evolution, we predict that a similar situation may also occur in humans.
DISCUSSION
A large fraction of CTCF-bound sites in different human and mouse cell types are conserved within species 7, 16 , defining what we call constitutive CTCF-bound sites. Moreover, several of these CTCF-bound sites lie within sequence stretches conserved between human and mouse genomes, and therefore are evolutionarily conserved in mammals 16 . However, we think that this criterion is too restrictive. CTCF sites may serve similar insulator or enhancer-blocking functions in two species if they are located at equivalent genomic positions (that is, are syntenic), regardless of whether they are located in conserved sequences. Therefore, in this study we extended the set of conserved CTCF-bound sites to include those that are syntenic. Using this approach, we identified at least twice as many likely equivalent CTCFbound sites in mammalian genomes than by using only sequence conservation, corresponding to 18% of the human constitutive sites. To search for deeply conserved CTCF syntenic sites in a nonmammalian genome, we determined by ChIP-Seq the genome-wide CTCF distribution in two chicken cell types. As in other species, a large fraction of CTCF sites were constitutively occupied in the two different chicken cell types we analyzed (59% of the sites from the cell type with fewer reads). Moreover, 7% of these chicken constitutive sites are located at syntenic positions in mice and humans, but most of them are not conserved at the sequence level. We call these sites CONSYN-CTCF sites. We therefore conclude that using synteny is a more useful way to identify equivalent positions occupied by a transcription factor in different species than using sequence conservation alone.
Notably, our work demonstrates that these deeply evolutionarily conserved CTCF-bound sites show enhancer-blocking activity and flank developmental genes associated with human diseases. Therefore, our work identifies a set of gene boundaries that have remained constant through evolution, at least from chicken to humans. This conservation may stem from the need to avoid regulatory interference within and between these essential genes. Disruption of these genes' boundaries would probably impair development or cause disease. Therefore, we propose that evolutionarily conserved CTCF sites can serve as a useful guide in assigning noncoding mutations to target genes, including those associated with human diseases. Indeed, as a proof of principle, in this study we used this knowledge of conserved gene boundaries to identify a probable target gene affected by haplotypes associated with an increased risk of multiple sclerosis located in the GFI1-EVI5 genomic region. Although EVI5 has been considered the target gene involved in this disease 22, 23 , we demonstrate that the last intron of this gene, which contains the multiple sclerosis risk haplotypes, is separated from its promoter by several syntenic CTCF-bound sites that can function as insulators. Indeed, the presence of these syntenic CTCF-bound sites suggests that the last EVI5 intron is within the GFI1 gene regulatory landscape. Therefore, CTCF could potentially prevents the interaction of several GFI1 regulatory elements present in this EVI5 intron with EV15's own promoter. Accordingly, evi5 expression is misregulated in zebrafish embryos with reduced CTCF function. We also found two repressor elements within this intron that are candidate regions for mutation in multiple sclerosis risk haplotypes. Accordingly, as we expected on the basis of malfunction of these repressors, we found that individuals carrying homozygosity in one of the multiple sclerosis risk SNPs have higher expression of GFI1, but not EVI5, in peripheral blood cells. Finally, in these cell types, and using 3C experiments, we further demonstrated that these repressors physically contact with the GFI1 promoter, but not that of EVI5. Taken together, our results indicate that GFI1, but not EVI5, is potentially associated with higher risk of developing multiple sclerosis; this prediction was originally based a r t i c l e s on the distribution of syntenic CTCF sites in multiple vertebrates. Therefore, the location of these sites might clarify the associations between disease-linked SNPs at noncoding DNA and target genes by defining regulatory domains throughout the genome.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Accession codes. GEO: chicken CTCF binding maps, GSE27945; mouse CTCF binding maps, GSE27944.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
